Quantinno Capital Management LP Has $14.51 Million Stock Position in GE HealthCare Technologies Inc. $GEHC

Quantinno Capital Management LP lifted its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 25.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 203,775 shares of the company’s stock after purchasing an additional 41,439 shares during the quarter. Quantinno Capital Management LP’s holdings in GE HealthCare Technologies were worth $14,505,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in GE HealthCare Technologies by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 52,275,767 shares of the company’s stock valued at $4,287,658,000 after buying an additional 267,058 shares in the last quarter. Auto Owners Insurance Co boosted its holdings in GE HealthCare Technologies by 9,525.4% in the fourth quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock worth $278,725,000 after acquiring an additional 33,629,559 shares in the last quarter. Dodge & Cox boosted its holdings in GE HealthCare Technologies by 13.4% in the fourth quarter. Dodge & Cox now owns 31,211,229 shares of the company’s stock worth $2,559,945,000 after acquiring an additional 3,693,918 shares in the last quarter. Capital Research Global Investors grew its stake in GE HealthCare Technologies by 1.6% in the fourth quarter. Capital Research Global Investors now owns 25,362,352 shares of the company’s stock valued at $2,080,248,000 after acquiring an additional 389,796 shares during the period. Finally, State Street Corp grew its stake in GE HealthCare Technologies by 2.0% in the fourth quarter. State Street Corp now owns 20,049,677 shares of the company’s stock valued at $1,644,475,000 after acquiring an additional 401,932 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GEHC. JPMorgan Chase & Co. decreased their price target on shares of GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a research note on Thursday, April 30th. Royal Bank Of Canada assumed coverage on shares of GE HealthCare Technologies in a report on Tuesday, June 23rd. They set an “outperform” rating and a $80.00 price objective for the company. Mizuho decreased their target price on shares of GE HealthCare Technologies from $90.00 to $80.00 in a research report on Thursday, April 30th. UBS Group raised their price target on shares of GE HealthCare Technologies from $67.00 to $73.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Hovde Group started coverage on GE HealthCare Technologies in a research note on Friday, July 17th. They issued a “market perform” rating and a $14.00 price objective for the company. Ten analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, GE HealthCare Technologies has a consensus rating of “Hold” and a consensus target price of $77.73.

Insider Buying and Selling at GE HealthCare Technologies

In other news, Director Kevin Lobo bought 10,000 shares of the stock in a transaction on Friday, May 22nd. The shares were purchased at an average cost of $64.18 per share, for a total transaction of $641,800.00. Following the completion of the purchase, the director directly owned 14,363 shares in the company, valued at $921,817.34. This represents a 229.20% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Watkin Phoebe L. Yang purchased 1,000 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were purchased at an average cost of $63.01 per share, for a total transaction of $63,010.00. Following the transaction, the director directly owned 13,702 shares in the company, valued at approximately $863,363.02. The trade was a 7.87% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 12,618 shares of company stock valued at $805,175. Company insiders own 0.36% of the company’s stock.

GE HealthCare Technologies Stock Performance

NASDAQ GEHC opened at $68.02 on Monday. The company has a market capitalization of $30.72 billion, a PE ratio of 15.60, a price-to-earnings-growth ratio of 1.97 and a beta of 0.69. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.97 and a current ratio of 1.26. GE HealthCare Technologies Inc. has a 52-week low of $58.75 and a 52-week high of $89.77. The company has a 50-day simple moving average of $64.02 and a 200 day simple moving average of $70.43.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Wednesday, July 29th. The company reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.04 by $0.09. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.26 billion. During the same period in the previous year, the company earned $1.06 earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis. On average, research analysts predict that GE HealthCare Technologies Inc. will post 4.91 EPS for the current year.

GE HealthCare Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Friday, July 24th will be paid a $0.035 dividend. The ex-dividend date is Friday, July 24th. This represents a $0.14 annualized dividend and a yield of 0.2%. GE HealthCare Technologies’s dividend payout ratio is presently 3.21%.

Key Stories Impacting GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Better-than-expected earnings and raised guidance: GE HealthCare reported adjusted earnings of $1.13 per share, exceeding the $1.04 consensus estimate, while revenue of $5.30 billion also topped expectations. Revenue increased 5.8% year over year, and management raised its full-year EPS outlook. GE HealthCare Q2 2026 Earnings Call Summary
• Positive Sentiment: Record backlog and solid demand: Strong orders growth and a record backlog support expectations for future revenue growth and helped reinforce the bullish case for GEHC. Analysts highlighted the backlog as evidence of durable demand for the company’s medical technology and imaging products. GE HealthCare Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support increased: Wells Fargo raised its price target from $75 to $85 and maintained an “overweight” rating. BTIG Research also forecast substantial appreciation, providing additional support for the shares. Wells Fargo Raises GE HealthCare Price Target
• Neutral Sentiment: Execution remains a key issue: Some analysis described demand as strong but execution as weaker, suggesting investors will watch margins, delivery performance and the company’s ability to convert its backlog into sustained earnings growth. GE HealthCare Strong Demand, Weak Execution
• Negative Sentiment: Shareholder investigations create legal uncertainty: Multiple law firms announced or continued investigations into possible securities-law violations and solicited investors who lost money. These announcements do not establish wrongdoing, but they may weigh on sentiment and raise potential litigation concerns. GEHC Securities Fraud Investigation

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.